Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy.
about
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissuesInherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involvedArtonin E Induces Apoptosis via Mitochondrial Dysregulation in SKOV-3 Ovarian Cancer CellsTRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.Cytosolic Hsp90α and its mitochondrial isoform Trap1 are differentially required in a breast cancer model.Clickable NAD analogues for labeling substrate proteins of poly(ADP-ribose) polymerases.Heat shock protein expression and temperature distribution in prostate tumours treated with laser irradiation and nanoshells.Inhibition of heat-induced apoptosis in rat small intestine and IEC-6 cells through the AKT signaling pathway.Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancerCorrelation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancerRole of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumPast, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells.Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors.A survey and analysis of the role of molecular chaperone proteins and imidazole-containing dipeptide-based compounds as molecular escorts into the skin during stress, injury, water structuring and other types of cutaneous pathophysiology.New insights into TRAP1 pathway.Heat shock proteins in cancer: targeting the 'chaperones'.Organelle-specific Hsp90 inhibitors.Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment.Tumor Necrosis Factor-Associated Protein 1 (TRAP1) is Released from the Mitochondria Following 6-hydroxydopamine Treatment.Berberine Regulated Lipid Metabolism in the Presence of C75, Compound C, and TOFA in Breast Cancer Cell Line MCF-7.Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer.Suppression of tumor necrosis factor receptor-associated protein 1 expression induces inhibition of cell proliferation and tumor growth in human esophageal cancer cells.TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins.The expanding proteome of the molecular chaperone HSP90.Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1.TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumorsTargeting Heat Shock Proteins in Cancer: A Promising Therapeutic ApproachProtein refolding in peroxisomes is dependent upon an HSF1-regulated function.Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells.Heat shock proteins and DNA repair mechanisms: an updated overview.Expression of TRAP1 predicts poor survival of malignant glioma patients.Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.
P2860
Q28468570-3BE031A9-DB79-4FF9-A770-DF971D8A7B9AQ28486233-993DCF5E-71B8-4F8B-AFC3-3A7C41EA85C1Q28551015-6DB046B5-142B-45D7-89A9-1C54F4214942Q30833632-C8B2E569-864E-4BC5-93E0-20B50A79EEEAQ33566518-42B39562-C8B4-4288-8D59-4FA9D67FEAACQ33990380-A2CEB099-D9DF-40E8-93A4-10B7509AAB6BQ34078406-E042F32E-9170-4449-B822-A839157A60A5Q34455692-780FD59C-7947-4D28-9627-44343841B326Q34609315-05585723-0173-46AC-BE3E-BB96090F4D95Q34647535-73B87D32-AEF1-4375-ABB6-88FDA392274EQ36378835-6E353AA0-F7BA-4338-A4C3-373EF5C9C166Q36498614-319FF90B-30CE-49B5-81A8-1F3ACE9A5C77Q37004579-FABB04EC-458C-498B-967F-64B32FD6FEF1Q37525035-2CFE09AE-0FF6-4AE1-AAD9-E7F97AB01A04Q37764922-988454E7-4D55-4A9A-A8D7-299280E19F95Q37995191-1FBC4455-CFC0-4E16-94C4-2D8B8D32BA94Q38008726-01A09061-16A9-4C34-AB85-41C1BBDD64F8Q38551234-D4EDCF1F-8590-46F5-9A52-7680FBAB92B4Q38674303-7AFB0176-E0A4-4EB5-B4D0-25E2E0CE6972Q38725685-75503D8A-10DB-496F-8BAD-CC510645E4E1Q38836725-25C545CB-B277-4022-BF60-DE064C8D071FQ38959970-1406B20E-9338-41B3-88C3-DEEFB83286AFQ39002125-4E357FB9-C693-4B1D-8ACC-3E741DB12701Q39462054-B1B4CC77-B560-4AA0-8E12-7E25CCABEE6BQ39640356-8E3876F5-4841-4C24-948A-B2534D9D12C8Q41134535-C19C057A-B232-4DA9-8678-D3944A74F5D6Q41135356-86E38761-D88A-4B58-BC13-BFCB02CE7579Q41660505-A6599AB4-20E1-4C00-A4BC-CE8D89E3A8A5Q42509266-3DA83A21-A37D-4BED-AFFA-56E44AFDA0F3Q42548853-6B8D8C49-9174-4998-A551-20DD2237AD90Q47738263-7BE2F733-8CAB-40AE-BA64-DFD7E28FB901Q48564233-E09888B9-3D2B-4761-BB60-FC0279703EEDQ55311424-B4555BAB-473E-4014-8DF7-FDA74F57001B
P2860
Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@en
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@nl
type
label
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@en
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@nl
prefLabel
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@en
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@nl
P50
P1433
P1476
Heat shock proteins, cell surv ...... et for ovarian cancer therapy.
@en
P2093
Annamaria Piscazzi
P304
P356
10.1016/J.YGYNO.2009.10.078
P407
P577
2009-11-25T00:00:00Z